The St. Baldrick's Foundation in Monrovia, California, has announced fifty-five grants totaling $17.5 million in support of physician-scientists working to advance innovative treatments for pediatric cancers.
Recipients include a team led by George-Lucian Moldovan at Penn State University College of Medicine that is studying the role of PARP inhibitors, which attempt to "fix" DNA damage that occurs in tumors, and a team led by Wendy Bottinor at Vanderbilt University Medical Center that is using cardiac imaging techniques to identify cardiovascular dysfunction in cancer survivors. Other recipients include research teams at the University of Chicago Medicine, the Dana-Farber Cancer Institute in Boston, the NYU School of Medicine in New York City, Baylor College of Medicine in Houston, and the Fred Hutchinson Cancer Research Center in Seattle.
Since 2005, St. Baldrick's has awarded more than $279 million in support of childhood cancer research.
"I'm humbled by the hard work of St. Baldrick's volunteers and the generosity of our donors," said the foundation's CEO, Kathleen Ruddy. "Their unified efforts, together with those of the childhood cancer research community and our employees, enable us to identify research proposals with the greatest potential to improve the chance of survival and the long-term lives of children fighting cancer. As no single research institution has a monopoly on talent or innovation, our supporters make the best research possible, wherever the ideas are, and because of them, St. Baldrick's continues to lead the charge to take childhood back from cancer."